Beta-carbolines as positive allosteric modulators of the human serotonin receptor 2C (5-HT2C)
US11485734B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Oct 2, 2019 |
| Grant date | Nov 1, 2022 |
| Priority date | — |
| Expiry date | Oct 2, 2039 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P25/36
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are novel small molecules, methods of synthesis of the small molecules, and uses of the small molecules for modulating activity of the human serotonin receptor 2C (5-HT2c), preferably selectively. The small molecules have a substituted beta-carboline core structure, which optionally may be saturated at one or more bonds to provide a dihydro-beta-carboline core or a tetrahydro-beta-carboline core. The small molecules may be administered to treat and/or prevent diseases, disorders, and/or conditions associated with human serotonin receptor 2C (5-HT2C) including psychiatric, mental, and/or neurological diseases, disorders, and conditions such as cognitive impairment, addiction, and obsessive compulsive disorder. The disclosed small molecules also may be administered to treat and/or prevent obesity, for example, via appetite suppression.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.